"Thromboxane A2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).
| Descriptor ID |
D013928
|
| MeSH Number(s) |
D10.251.355.255.100.825.800 D10.251.355.310.166.971.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thromboxane A2".
Below are MeSH descriptors whose meaning is more specific than "Thromboxane A2".
This graph shows the total number of publications written about "Thromboxane A2" by people in this website by year, and whether "Thromboxane A2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thromboxane A2" by people in Profiles.
-
Kakouros N, Gluckman TJ, Conte JV, Kickler TS, Laws K, Barton BA, Rade JJ. Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long-Term Outcome After Cardiac Surgery. J Am Heart Assoc. 2017 Nov 02; 6(11).
-
DeFilippis AP, Oloyede OS, Andrikopoulou E, Saenger AK, Palachuvattil JM, Fasoro YA, Guallar E, Blumenthal RS, Kickler TS, Jaffe AS, Gerstenblith G, Schulman SP, Rade JJ. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction. Circ J. 2013; 77(11):2786-92.
-
Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44.
-
Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther. 2007 Sep; 5(5):969-75.
-
Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation. 2006 Jun 27; 113(25):2865-7.
-
Song Y, Jones JE, Beppu H, Keaney JF, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation. 2005 Jul 26; 112(4):553-62.
-
O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41.
-
Daley JT, Brown ML, Watkins T, Traish AM, Huang YH, Moreland RB, De Tejada IS. Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. J Urol. 1996 Apr; 155(4):1482-7.
-
Uedelhoven WM, R?tzel A, Meese CO, Weber PC. Smoking alters thromboxane metabolism in man. Biochim Biophys Acta. 1991 Jan 28; 1081(2):197-201.